Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
- HAEMOPHILUS B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE) (HIBERIX)
- haemophilus b conjugate vaccine tetanus toxoid conjugate hiberix
- haemophilus influenzae type b conjugate vaccine tetanus toxoid conjugate
- haemophilus influenzae type b strain 20 752 capsular polysaccharide tetanus toxoid conjugate antigen
- HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20,752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN
- haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
- Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
- hib hiberix
- hiberix
- Hiberix
- Hiberix®
- Hiberix™
- HIBERIX™
- MENITORIX COMPONENT HAEMOPHILUS B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE)
- menitorix component haemophilus b conjugate vaccine tetanus toxoid conjugate
- First in class
- No
- Orphan designation
- No
- Condition
- Rotavirus Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002622
- Subject identifier
- D012400
- Condition
- Meningococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004249
- Subject identifier
- D008589
- Condition
- Streptococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001476
- Subject identifier
- D013290
- Condition identifier
- EFO_0004249
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001476
- Highest recorded phase
- 3
- NCT00344318
- NCT00547248
- NCT00814710
- NCT03207750
- NCT03621670
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (71)
- 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
- A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
- A Phase IV Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of Menitorix
- A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants
- A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.
- A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults
- A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
- Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination
- Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants
- Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants
- Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth
- Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
- Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine
- Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV
- Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
- Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
- Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants
- Does the Order in Which Vaccines Are Administered Affect Pain Response?
- Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
In development for (3)
- Meningococcal infection Phase 3
- Rotavirus infection Phase 3
- Streptococcal infection Phase 3